Thursday, October 30, 2014 - 08:08 HTG Molecular Diagnostics, Inc. (HTG), a provider of instruments and reagents for molecular profiling applications, today announced that it entered into an agreement with Illumina, Inc. (NASDAQ:ILMN), under which HTG will have the right to develop
Tuesday, October 14, 2014 - 08:14 HTG Molecular Diagnostics (“HTG”) today announced that it has closed a growth capital term loan facility with Silicon Valley Bank and Oxford Finance (SVB/Oxford). The loan facility provides HTG with up to $16 million of available proceeds, with $11 million funded
HTG receives US Patent for HTG EdgeSeq chemistry coupling quantitative nuclease protection with next-generation-sequencing TUCSON, AZ--(Marketwired - Jun 17, 2014 ) - HTG Molecular Diagnostics, a provider of instruments and reagents for translational research and molecular diagnostics, today
HTG launches an automated, sequencing-based miRNA Whole Transcriptome digital gene expression assay for challenging sample types TUCSON, Ariz. (June 10, 2014) – Today HTG Molecular Diagnostics announced the availability of HTG EdgeSeq miRNA Whole Transcriptome Assay for measuring the expression of
TUCSON, Ariz. (April 9, 2014) HTG Molecular Diagnostics, Inc., (HTG) today announced that Patrick Roche, Ph.D., has joined the company as Sr. Vice President for IVD Assay Development. Dr. Roche joins HTG from Ventana Medical Systems/Roche Tissue Diagnostics where he served as Vice President of
HTG Molecular Diagnostics and OvaGene Oncology Partner on Gynecologic Cancer Tests TUCSON, Ariz. (April 7, 2014) HTG Molecular Diagnostics, Inc., (HTG) and OvaGene Oncology have entered a manufacturing supply agreement where OvaGene will design and develop their proprietary gene
Lewis Shuster Joins HTG Molecular Diagnostics Board of Directors TUCSON, Ariz. (March 21, 2014) HTG Molecular Diagnostics, Inc., (HTG) today announced that Lewis (Lew) Shuster has joined its board of directors. Mr. Shuster is CEO of Shuster Capital, a strategic and operating advisory firm to life
TUCSON, Ariz. (February 11, 2014) HTG Molecular Diagnostics (“HTG”) today announced the initial closing of its Series E offering with existing investors Novo Ventures, SROne, Merck Capital Ventures, and Fletcher Spaght. Proceeds will support commercial and product development initiatives.
Tucson, Ariz. (September 25, 2013) - The Centre of Excellence for the Prevention of Organ Failure (PROOF Centre) and HTG Molecular Diagnostics are collaborating to begin clinical validation of a biomarker blood test that will provide early indication of organ rejection in heart transplant patients.
TUCSON, Ariz. (September 4, 2013) – The National Human Genome Research Institute of the National Institutes of Health issued a Notice of Award granting a Phase II SBIR award of $1.01 million for HTG Molecular Diagnostics to continue the Nuclease Probe Mediated Sequencing Project (HTG EdgeSeq).